New hope for tough hepatitis c cases: triple therapy shows promise
NCT ID NCT02647632
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measure of success was whether the virus remained undetectable 12 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin
What this could lead to
If successful, this could offer a new treatment option for people with hepatitis C who did not get better with standard therapies.
What could go wrong
This is a small, early-phase study with only 26 participants. Results may not apply to everyone, and the combination may cause side effects or fail to clear the virus in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALRIC Laurent
Toulouse, 31059, France
-
ASSELAH Tarik
Clichy, 92110, France
-
BOURLIERE Marc
Marseille, 13285, France
-
Christophe HEZODE
Créteil, 94010, France
-
JEZEQUEL Caroline
Rennes, 35033, France
-
LARREY Dominique
Montpellier, 34295, France
-
LEROY Vincent
Grenoble, 38043, France
-
METIVIER Sophie
Toulouse, 31059, France
-
POL Stanislas
Paris, 75679, France
-
SAMUEL Didier
Villejuif, 94804, France
-
SERFATY Lawrence
Paris, 75571, France
-
TRAN Albert
Nice, 06202, France
-
ZOULIM Fabien
Lyon, 69317, France